Storia in 3 fonti

Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Amgen (NASDAQ:AMGN)

Amgen challenges FDA's proposed Tavneos withdrawal, seeks hearing, and cites independent Duke review of trial data.

Raccontata da

fiercepharma.com

benzinga.com

endpoints.news

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Amgen (NASDAQ:AMGN)

Amgen contests FDA's Tavneos withdrawal proposal via formal hearing request; clinical data due June 29, 2026. Approval reversal signals FDA's intensified post-market scrutiny for rare-disease therapies, raising the stakes for independent clinical validation in biotech regulatory decisions.

originale

endpoints.news1 mese fa

Amgen and the FDA want two different outcomes for Tavneos. What will patients do?

Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market.

Leggi questa versione →

Timeline cronologica

venerdì 12 giugno 2026·fiercepharma.com
FDA hearing on Amgen's Tavneos will include findings from an independent review
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare…
venerdì 12 giugno 2026·benzinga.com
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Amgen (NASDAQ:AMGN)
Amgen challenges FDA's proposed Tavneos withdrawal, seeks hearing, and cites independent Duke review of trial data.

Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Amgen (NASDAQ:AMGN)

Amgen and the FDA want two different outcomes for Tavneos. What will patients do?

Timeline cronologica

FDA hearing on Amgen's Tavneos will include findings from an independent review

Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Amgen (NASDAQ:AMGN)

FDA hearing on Amgen's Tavneos will include findings from an independent review

Amgen and the FDA want two different outcomes for Tavneos. What will patients do?